via Health Care https://ift.tt/QRFbMaP The years-long effort to yank the drug's approval offers a case study of the agency's accelerated approval program, which green-lit Makena in 2011.
Battle over pregnancy drug highlights risks of FDA expediting drugs to market
0 Comments